2025年晚期前列腺癌共识会议诊断专场:前列腺癌诊断与分期投票结果
2025年APCCC诊断专场作为试点项目,由科学委员会制定88个多项选择题,覆盖六大主题,会前由专家组成员进行网络投票,共识定义为≥75%同意,强共识为≥90%同意。最终仅17/88题(19%)达成共识,其中6题(7%)为强共识;各主题共识率从0%到44%不等。投票结果与讨论有助于指导诊断、分期及再分期中争议领域的临床管理,并为未来研究优先级提供参考。
要点
- 88个诊断与分期问题中仅19%达成共识,强共识仅7%。
- 「如何分期前列腺癌」共识率最高(44%),「监测转移性前列腺癌」为0%。
- 结果可辅助临床决策,尤其在高水平证据缺乏或矛盾的领域。
核心结论
- 2025年APCCC诊断专场投票在88个问题中仅17个(19%)达成共识,其中6个(7%)为强共识。
- 投票结果与讨论可帮助医生应对前列腺癌诊断、分期和再分期中的争议领域,并为研究资助者提供优先级参考。
研究设计与样本
- APCCC Diagnostics 2025为试点项目,科学委员会制定88个多项选择题,覆盖六个主题。
- 会前专家组成员通过基于网络的调查进行投票,共识定义为≥75%同意,强共识定义为≥90%同意。
主要发现
- 「如何诊断前列腺癌」17题中2题(14%)达成共识。
- 「如何分期前列腺癌」16题中7题(44%)达成共识。
- 「生化复发场景」14题中3题(21%)达成共识。
- 「转移性疾病:如何处理」11题中2题(18%)达成共识。
- 「监测转移性前列腺癌」18题中0题(0%)达成共识;「放射配体治疗与影像」12题中3题(25%)达成共识。
关键数值与推荐
- 共识判定标准:≥75%同意为共识,≥90%同意为强共识。
- 总体共识率:17/88题(19%)达成共识,其中6题(7%)为强共识。
临床怎么用
- 投票结果与讨论可协助医生在前列腺癌诊断、分期和再分期的争议领域进行临床管理,尤其在高水平证据缺乏或矛盾时。
- 研究结果可帮助资助者和政策制定者确定未来研究的优先领域。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: For over a decade the Advanced Prostate Cancer Consensus Conference (APCCC) covers a variety of topics that greatly impact daily practice. In 2025, a dedicated event was organised to discuss key questions in clinical management of patients with prostate cancer (PC) related to diagnostic tools (APCCC Diagnostics). Here we present the voting results of the APCCC Diagnostics questions. METHODS: APCCC Diagnostics 2025 is a pilot project. The scientific committee for APCCC Diagnostics 2025 developed 88 multiple-choice consensus questions on six different topics. Prior to the conference, the panel members (''panellists'') voted on these questions via a web-based survey. Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. KEY FINDINGS AND LIMITATIONS: Consensus was only reached on 17 of 88 questions (19%), of which six (7%) received a strong consensus. Specifically, consensus was reached for two of 17 questions (14%) in "how to diagnose PC"; seven of 16 (44%) in "how to stage PC"; three of 14 (21%) in "Biochemical Recurrence Scenario"; two of 11 (18%) in "metastatic disease: what to do?"; zero of 18 (0%) in "monitoring metastatic PC"; and three of 12 (25%) in "radioligand therapy and imaging." CONCLUSIONS AND CLINICAL IMPLICATIONS: The voting results and their discussion may assist physicians in navigating controversial areas of clinical management related to diagnosis, staging, and restaging in the different clinical settings for PC, particularly where high-level evidence is scarce or conflicting. The findings can also help funders and policymakers in prioritising areas for future research.
引用
- Fanti S, Turco F, Tombal B, et al. Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics. Eur Urol. 2026. PMID: 42399196. doi:10.1016/j.eururo.2026.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。